Welcome to our dedicated page for Thiogenesis news (Ticker: TTIPF), a resource for investors and traders seeking the latest updates and insights on Thiogenesis stock.
Thiogenesis Therapeutics, Corp. (OTCQX: TTIPF) is a clinical-stage biopharmaceutical company developing sulfur-containing and thiol-based prodrugs for serious pediatric and inherited diseases, particularly rare mitochondrial and metabolic disorders. The Thiogenesis news stream highlights how its lead candidate, TTI-0102, progresses through clinical development and regulatory interactions.
News releases from the company focus heavily on clinical milestones for TTI-0102. These include updates on its randomized, double-blind, placebo-controlled Phase 2 trial in Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) in Europe, interim analyses describing biomarker activity and biological proof-of-concept, and activation of additional European trial sites. Thiogenesis also reports on plans and regulatory clearances for a Phase 2a trial in Leigh syndrome spectrum in the United States, as well as preparations for a Phase 3 pivotal trial in nephropathic cystinosis and a Phase 2 or Phase 2a trial in pediatric Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Investors and observers can use the TTIPF news page to follow announcements about scientific presentations at mitochondrial disease conferences, late-breaking abstract acceptances, and participation in webinars and panel discussions organized by patient advocacy and research organizations. Corporate updates such as private placements, stock option grants, investor relations agreements, and patent developments related to asymmetric disulfide prodrugs of cysteamine are also reflected in the news flow.
By reviewing Thiogenesis Therapeutics news, readers gain insight into the timing and design of its clinical trials, the company’s focus on mitochondrial oxidative stress and thiol biology, and the regulatory guidance it receives in key jurisdictions. The news page can be revisited regularly to see how the TTIPF development pipeline and corporate strategy evolve over time based on company disclosures.
Thiogenesis Therapeutics (OTCQX: TTIPF) has initiated its Phase 2 clinical trial for TTI-0102, its lead product candidate targeting MELAS (Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes). The first two patients were dosed on May 12th at Radboud University Medical Center in Netherlands.
The multi-center trial will be conducted in the Netherlands and France, enrolling 12 patients total (8 receiving TTI-0102, 4 receiving placebo) in a randomized, double-blind, placebo-controlled study over 6 months. Key clinical endpoints include the 12-Minute Walking Test, Fatigue Severity Scale, and Quality of Life Assessment, with an interim analysis planned at 3 months.
TTI-0102 is designed to increase intracellular antioxidant glutathione and amino acid taurine, both deficient in MELAS patients. Currently, there are no approved drugs for MELAS in the EU or U.S.
Thiogenesis Therapeutics (TSXV: TTI) (OTCQX: TTIPF), a clinical-stage biotech company, has entered into a consulting and investor relations agreement with Bull Markets Media GmbH, effective February 15, 2025. The German-based digital stock market news portal will analyze opportunities to expand the company's European shareholder base and network.
The agreement includes a C$60,000 consulting fee, with 50% payable upon signing and the remainder due June 1, 2025. Additionally, the consultant will receive 100,000 stock options at $0.64 per share, valid for 3 years, vesting in four equal tranches of 25,000 between May 2025 and February 2026. The 12-month agreement can be renewed annually for up to two additional years.
The TSXV has also given final acceptance of Thiogenesis's IR contract with Triomphe Holdings (Capital Analytica).
Thiogenesis Therapeutics (TSXV: TTI) (OTCQX: TTIPF) has announced its common shares are now trading on the OTCQX Best Market under the symbol TTIPF. This represents a significant milestone as OTCQX is the highest-level market of OTC Markets, hosting 12,000 U.S. and global securities.
The company has also secured DTC eligibility status, enabling electronic settlement of shares across the United States and 131 other countries. Thiogenesis will maintain its listing on the TSX Venture Exchange under TTI.
Additionally, the company recently received final regulatory clearance to initiate a Phase 2 clinical trial in Europe for the treatment of Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like episodes (MELAS). The trial's commencement is pending completion of administrative procedures and material provision to trial sites.
Thiogenesis Therapeutics (TSXV: TTI) has received final EMA clearance for its Clinical Trial Application (CTA) Part II to begin a Phase 2 clinical trial of TTI-0102 for MELAS treatment. The trial will be conducted in France and the Netherlands as a randomized, double-blind, placebo-controlled study over 6 months.
The study will involve 12 patients total, with 8 receiving TTI-0102 and 4 receiving placebo. An interim analysis will be conducted after 3 months to assess safety data, pharmacokinetics/pharmacodynamics, and biomarkers. The trial's efficacy endpoints include the 12-Minute Walking Test, Fatigue Severity Scale, and Quality of Life Assessment.
TTI-0102 is designed to increase intracellular antioxidant glutathione and amino acid taurine levels, which are typically deficient in MELAS patients. Currently, there are no approved drugs for MELAS treatment.
Thiogenesis Therapeutics presented updates on two clinical programs in mitochondrial disease at the UMDF Webcast. The company received acceptance of its Clinical Trial Application Part I for MELAS in Europe and submitted Part II in December 2024, planning a Phase 2 trial with 12 patients in Netherlands and France by Q1 2025.
For Leigh Syndrome (LS), following a pre-IND meeting with the FDA in November 2024, the company is filing an IND and plans to initiate a Phase 2a trial in Q1 2025. The company's lead product, TTI-0102, targets oxidative stress in both conditions. MELAS affects approximately 15,000 patients in the US and 20,000 in the EU, while LS occurs in about 1/40,000 births.
Thiogenesis Therapeutics (TSXV: TTI, OTC: TTIPF) has achieved DTC eligibility status in the U.S., enabling electronic settlement of its common shares and supporting its future U.S. listing plans. The company participated in the CEM conference in Miami for investor outreach. Additionally, Thiogenesis issued 521,800 shares at $0.50 per share from exercised Finder's Options, generating $260,900. The company reported $4.15 million in cash and cash equivalents as of September 30, 2024.